Research

Energy balance

Current glucose-lowering therapies for Type 2 diabetes show no benefit in reducing the risk of macrovascular events.

Clinicians should reconsider the reliance on glucose-lowering therapies for cardiovascular protection.

StrongRefutesmedium confidence
Large clinical trials of current glucose-lowering therapies for Type 2 diabetes have shown no benefit in reducing the risk of macrovascular events.
Andrew MN Walker et al. · Expert Review of Endocrinology & Metabolism · 2014

Why this rating

Based on the context of large clinical trials.

Source

Contemporary treatment strategies for Type 2 diabetes-related macrovascular disease

Andrew MN Walker et al. · Expert Review of Endocrinology & Metabolism · 2014

DOI 10.1586/17446651.2014.941356

reviewCited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →